Trial · NCT03740165
Results by group60
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 60
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Tumors (Combined Positive Score [CPS]≥10) | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | 23.9 | 95% Confidence Interval 21.0 to 30.2 | Months | |
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Tumors (Combined Positive Score [CPS]≥10) | Carboplatin + Paclitaxel + Pembrolizumab | 17.3 | 95% Confidence Interval 15.2 to 19.4 | Months | |
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Tumors (Combined Positive Score [CPS]≥10) | Carboplatin + Paclitaxel | 15.2 | 95% Confidence Interval 12.5 to 17.2 | Months | |
| PFS Per RECIST 1.1 as Assessed by the Investigator in All Participants | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | 22.2 | 95% Confidence Interval 18.8 to 24.7 | Months | |
| PFS Per RECIST 1.1 as Assessed by the Investigator in All Participants | Carboplatin + Paclitaxel + Pembrolizumab | 15.2 | 95% Confidence Interval 13.6 to 16.4 | Months | |
| PFS Per RECIST 1.1 as Assessed by the Investigator in All Participants | Carboplatin + Paclitaxel | 14.6 | 95% Confidence Interval 12.7 to 16.3 | Months | |
| Overall Survival (OS) in Participants With PD-L1 Positive Tumors (CPS ≥ 10) | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | 50.2 | 95% Confidence Interval 43.9 to NA | Months | |
| Overall Survival (OS) in Participants With PD-L1 Positive Tumors (CPS ≥ 10) | Carboplatin + Paclitaxel + Pembrolizumab | 56.4 | 95% Confidence Interval 42.4 to NA | Months | |
| Overall Survival (OS) in Participants With PD-L1 Positive Tumors (CPS ≥ 10) | Carboplatin + Paclitaxel | 51.6 | 95% Confidence Interval 41.8 to NA | Months | |
| OS in All Participants | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | 47.7 | 95% Confidence Interval 42.3 to 54.9 | Months | |
| OS in All Participants | Carboplatin + Paclitaxel + Pembrolizumab | 44.2 | 95% Confidence Interval 38.1 to 52.2 | Months | |
| OS in All Participants | Carboplatin + Paclitaxel | 47.1 | 95% Confidence Interval 41.7 to 60.9 | Months | |
| PFS Per RECIST 1.1 as Assessed by Blinded Independent Central Review (BICR) in Participants With PD-L1 Positive Tumors (CPS≥10) | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | 42.0 | 95% Confidence Interval 27.2 to 51.9 | Months | |
| PFS Per RECIST 1.1 as Assessed by Blinded Independent Central Review (BICR) in Participants With PD-L1 Positive Tumors (CPS≥10) | Carboplatin + Paclitaxel + Pembrolizumab | 20.3 | 95% Confidence Interval 17.3 to 27.4 | Months | |
| PFS Per RECIST 1.1 as Assessed by Blinded Independent Central Review (BICR) in Participants With PD-L1 Positive Tumors (CPS≥10) | Carboplatin + Paclitaxel | 22.1 | 95% Confidence Interval 15.4 to 29.5 | Months | |
| PFS Per RECIST 1.1 as Assessed by BICR in All Participants | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | 30.1 | 95% Confidence Interval 24.0 to 37.3 | Months | |
| PFS Per RECIST 1.1 as Assessed by BICR in All Participants | Carboplatin + Paclitaxel + Pembrolizumab | 19.0 | 95% Confidence Interval 16.6 to 22.2 | Months | |
| PFS Per RECIST 1.1 as Assessed by BICR in All Participants | Carboplatin + Paclitaxel | 20.8 | 95% Confidence Interval 16.9 to 25.3 | Months | |
| PFS After Second-line Treatment (PFS2) Following Discontinuation of Study Treatment as Assessed by the Investigator in Participants With PD-L1 Positive Tumors (CPS≥10) | Carboplatin + Paclitaxel + Pembrolizumab + Olaparib | 41.1 | 95% Confidence Interval 32.3 to 52.1 | Months | |
| PFS After Second-line Treatment (PFS2) Following Discontinuation of Study Treatment as Assessed by the Investigator in Participants With PD-L1 Positive Tumors (CPS≥10) | Carboplatin + Paclitaxel + Pembrolizumab | 34.1 | 95% Confidence Interval 29.0 to 41.2 | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03740165/results